Biomarker prediction of clinical outcome in operable breast cancer patients treated with tamoxifen

E. Scarpi, F. De Paola, M. Sarti, P. Bajorko, A. M. Granato, A. Volpi, O. Nanni, R. Maltoni, D. Amadori

Research output: Contribution to journalArticlepeer-review


The predictivity of tumour size, oestrogen (ER) and progesterone (PgR) receptors, 3H-thymidine labelling index (TLI), c-erbB-2 and p27kip1 expression on clinical outcome was analysed on a consecutive series of 118 postmenopausal patients with ER-positive, node-positive tumours. All patients were treated with surgery ± radiotherapy and adjuvant tamoxifen (30 mg/day) for at least 2 years. TLI, ER, c-erbB-2 and p27kip1 were generally unrelated to each other. PgR was directly related to ER and inversely to c-erbB-2. Tumour size was inversely related to both c-erbB-2 and p27kip1 expression. At a median follow-up of 75 months, 5-year relapse-free survival was significantly lower for patients with very rapidly proliferating (HR = 2.61, 95% CI = 1.34-5.08), PgR negative (HR = 2.76, 95% CI = 1.43-5.33) or relatively low ER content (HR = 2.20, 95% CI = 1.14-4.25) tumours than for patients with tumours expressing the opposite biological profiles. Overall survival was also significantly different as a function of TLI (HR = 3.47, 95% CI = 1.52-7.93) and PgR (HR = 2.27, 95% CI = 1.00-5.15). TLI and PgR maintained an independent relevance in multivariate analysis and together were capable of identifying subgroups of patients at significantly different risk of relapse and death.

Original languageEnglish
Pages (from-to)101-110
Number of pages10
JournalBreast Cancer Research and Treatment
Issue number2
Publication statusPublished - 2001


  • Biomarkers
  • N ER breast cancer
  • Predictivity
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Biomarker prediction of clinical outcome in operable breast cancer patients treated with tamoxifen'. Together they form a unique fingerprint.

Cite this